CoChat

Incretins and other peptides in the treatment of diabetes

Open access
Todd, J. F., Bloom, S. R. · 2007 · Diabetic Medicine
Cited by 76

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Glucagon‐like peptide‐1 (7‐36) amide (GLP‐1) is a gut hormone, released postprandially, which stimulates insulin secretion and insulin gene expression as well as pancreatic B‐cell growth. Together with glucose‐dependent insulinotropic polypeptide (GIP), it is responsible for the incretin effect which is the augmentation of insulin secretion following oral administration of glucose. Patients with Type 2 diabetes have greatly impaired or absent incretin‐mediated insulin secretion which is mainly as a result of decreased secretion of GLP‐1. However, the insulinotropic action of GLP‐1 is preserved in patients with Type 2 diabetes, and this has encouraged attempts to treat Type 2 diabetic patients with GLP‐1. GLP‐1 also possesses a number of potential advantages over existing agents for the treatment of Type 2 diabetes. In addition to stimulating insulin secretion and promoting pancreatic B‐cell mass, GLP‐1 suppresses glucagon secretion, delays gastric emptying and inhibits food intake. Continuous intravenous and subcutaneous administration significantly improves glycaemic control and causes reductions in both HbA 1c and body weight. However, GLP‐1 is metabolized extremely rapidly in the circulation by the enzyme dipeptidyl peptidase IV (DPP‐IV). This is the probable explanation for the short‐lived effect of single doses of native GLP‐1, making it an unlikely glucose‐lowering agent. The DPP‐IV resistant analogue, exenatide, has Food and Drug Administration (FDA) approval for the treatment of Type 2 diabetes and selective DPP‐IV inhibitors are under development. Both approaches have demonstrated remarkable efficacy in animal models and human clinical studies. Both are well tolerated and appear to have advantages over current therapies for Type 2 diabetes, particularly in terms of the effects on pancreatic B‐cell restoration and potential weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2006.02071.x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 76

Metadata

Authors
Todd, J. F., & Bloom, S. R.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2007-02-14
Volume
24
Issue
3
Pages
223-232
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2092533097
Cited by
76
References
28
FWCI
6.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incretins and other peptides in the treatment of diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2006.02071.x
The paper
Todd, J. F., & Bloom, S. R. (2007). Incretins and other peptides in the treatment of diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2006.02071.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.